Navigation Links
Compound Targets, Destroys Cancer Stem Cells in Mice
Date:8/13/2009

Therapeutic possibilities are uncertain, researchers say

THURSDAY, Aug. 13 (HealthDay News) -- Researchers have identified a chemical able to seek out and destroy the stem cells that scientists believe give rise to cancer recurrence after treatment.

A growing body of research is showing that cancer stem cells play a role in cancer metastasis and in causing cancer to reappear even after treatment seems to have eradicated the initial tumor.

"Evidence is accumulating rapidly that cancer stem cells are responsible for the aggressive powers of many tumors," including breast, prostate, lung and others, said study author Robert Weinberg, a member of the Whitehead Institute for Biomedical Research at Massachusetts Institute of Technology.

Yet studying cancer stem cells in the lab has proven problematic. The cells, already fewer in number than other types of tumor cells, tend to lose their stem cell-like properties when grown outside the body.

In the study, which appears in the Aug. 13 online issue of Cell, researchers were able to generate large numbers of cancer cells with stem cell-like qualities through a technique called "epithelial-to-mesenchymal transition," which causes the cells to take on characteristics similar to stem cells.

"A critical aspect of our work was to generate relatively homogenous and stable populations of cancer stem-like cells that could then be used for screening," said co-lead study author Tamer Onder, a former graduate student at the Whitehead Institute for Biomedical Research and now postdoctoral research fellow at Children's Hospital in Boston. "We were able to achieve this by inducing the cancer cells into an epithelial-to-mesenchymal transition using novel reagents that we had developed in the lab."

Researchers then analyzed thousands of chemical compounds to determine which ones were effective in killing breast cancer stem cells.

They found that a chemical called salinomycin destroyed both lab-generated cancer stem cells, as well as naturally occurring ones. When compared to paclitaxel, a common breast cancer chemotherapy drug, salinomycin reduced the number of cancer stem cells by more than 100-fold and inhibited breast tumor regrowth in mice.

Researchers also looked at the effect of salinomycin on genes that previous research has implicated in very aggressive tumors. The study showed salinomycin decreased the activity of these genes, while paclitaxel didn't.

Additional research is needed to determine exactly how salinomycin works to kill cancer stem cells and if it will be as effective in humans as it was in mice, researchers said.

More information

There's more on cancer stem cells at the U.S. National Cancer Institute.



-- Jennifer Thomas



Source: Aug. 13, 2009, news release, Whitehead Institute for Biomedical Research


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. First compound that specifically kills cancer stem cells found
2. New class of compounds discovered for potential Alzheimers disease drug
3. DSM Announces SafeBridge(R) Potent Compound Safety Certification
4. New Compounding Pharmacy Videos Provide Product Information, Teach Safety
5. Novel light-sensitive compounds show promise for cancer therapy
6. Neuromed Announces that Merck & Co., Inc. Terminates Research Collaboration and License Agreement for Compounds Targeting N-Type Calcium Channels
7. New antibiotics could come from a DNA binding compound that kills bacteria in 2 minutes
8. Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers
9. Bayer to Present Data on Development Compound BAY 73-4506 at 45th Annual Meeting of the American Society of Clinical Oncology
10. Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009
11. GADA Points to Safety of FDA Approved Generics in Wake of Wellington Polo Horse Deaths from Compounded Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Compound Targets, Destroys Cancer Stem Cells in Mice
(Date:6/28/2017)... ... 28, 2017 , ... Eating disorders have the highest mortality rate of any ... person dies as a direct result from an eating disorder in the U.S. As ... The iaedp Foundation meets this challenge by offering what has become the leading certification ...
(Date:6/28/2017)... , ... June 28, 2017 , ... Park Systems ... AFM Luncheon for all SEMICONWest attendees and Park customers on July 11, ... talks from Dr. Sang-il Park, Chairman & CEO of Park Systems, and Prof. ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... financial consultations to communities in northern Virginia and DC, is announcing a cooperative ... for patients with Alzheimer’s and other disorders that lead to memory impairment. , ...
(Date:6/27/2017)... ... June 27, 2017 , ... DrugDev understands that ... they can trust the sponsor to pay them correctly and on time. As the ... establish payment strategies that encourage sites to work on their studies. , At a ...
(Date:6/27/2017)... ... June 27, 2017 , ... Building on the ... Louisiana became the sixth state to pass legislation which ensures that children can ... signature, Louisiana joins the states of Alabama, Arizona, Florida, Utah and Washington who ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... , June 6, 2017  Diplomat Specialty Infusion Group, a ... compounding environment to its Iowa location. ... Urbandale now features an ISO 7 cleanroom—the standard needed ... environment with a low level of pollutants. ... IV nutrition consumers and better serve our Iowa ...
(Date:6/1/2017)... 1, 2017 Nutriceutical Holdings (NH), parent company ... (VRS), and KD Pharma Group have decided to join ... KD Pharma Group. KD Pharma Group will become the ... acquire the entire company. "We believe we ... committed to growing the NH companies by providing us ...
(Date:5/26/2017)... 26, 2017  Endo International plc (NASDAQ: ENDP ... CEO, will represent the Company in a fireside chat at ... Tuesday, June 13, 2017 at 10:40 a.m. PT / 1:40 ... in Rancho Palos Verdes, CA. ... will be available on the Company,s website at http://www.endo.com/investors/overview ...
Breaking Medicine Technology: